Page 17 of 19 · 454 questions tagged vendor-vetting.
What I have: WXT · ChinaPeptides (QYAOBIO). I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can obtain either…
Conditions: ERP · Nantong Guangyuan Chemical. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can obtain either…
Setup, so nobody has to ask: method section · CPC. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…
Stated plainly: JEEP · Bachem Holding (Suzhou). I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a…
Setup, so nobody has to ask: 96.8% · mazdutide · Homopeptide. I am trying to build something sustainable rather than something thorough that I will abandon. I have…
The case in front of me: SGN · orforglipron. Before I write this off, I want to check whether it is a known failure mode. I have the lot number, the certificate and…
Setup, so nobody has to ask: list of related substances · GL Biochem. The figures are clear enough; the question is what they mean and what they do not. I can supply…
Conditions: WWB · Bachem Holding (Suzhou). I have used one of these for a while and I am considering switching, which requires a reason. What I care about is…
Numbers first: 98.4% · dulaglutide · QYB. This is a planning question. I know what my options are; I do not know how to weigh them. What I want is the minimum viable…
I am comparing a supplier certificate against an independent result on the same lot. I would like to know the limits of what can be inferred from this. What I am…
Details up front: 98.2% · dulaglutide · GGPeps. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone can tell me which…
Setup, so nobody has to ask: 98.2% · mazdutide · TFC. I am trying to build something sustainable rather than something thorough that I will abandon. I have already…
The particulars: mazdutide · lot-specific certificate. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at…
Details up front: method section · Homopeptide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…
Conditions: date of analysis · QST. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being…
I have the report as a PDF with the chromatogram on page two, so I can quote specifics. I want a method I can write down and repeat, not a rule of thumb. I would…
I have the report as a PDF with the chromatogram on page two, so I can quote specifics. I want a method I can write down and repeat, not a rule of thumb. I would…
The method section is present, which is unusual enough that I want to make use of it. I am trying to do this correctly the first time rather than learn it by getting…
Setup, so nobody has to ask: ERP · cagrilintide. This is not behaving the way I expected and I want to understand the discrepancy before I act on it. I have…
Concretely: QSC · cagrilintide. This is not behaving the way I expected and I want to understand the discrepancy before I act on it. I have photographed the current…
Numbers first: 95.2% · retatrutide · QYB. This is a planning question. I know what my options are; I do not know how to weigh them. What I want is the minimum viable…
The method section is present, which is unusual enough that I want to make use of it. I would like help reading this properly rather than being told what conclusion…
I have both a purity figure and a content figure, which is why the discrepancy is visible. I have the document in front of me and I can read the numbers. What I…
I have kept every message, invoice and document, which I gather is the useful habit. I would rather be corrected now than propagate something wrong. I am specifically…